Atrial Fibrillation Patients With Type 2 Diabetes Benefit From Non–Vitamin K Oral Anticoagulants

After a review of the epidemiology and pathophysiology of the connections between atrial fibrillation (AF) and type 2 diabetes, a team of researchers led by Anna Plitt, MD, of Mount Sinai Hospital, has concluded that many high-risk patients with both conditions may benefit from treatment with non-vitamin K antagonist oral anticoagulants (NOACs).